Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JADE: JNJ-56136379 in Chronic Hepatitis B
NCT03361956Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial of bersacapavir in Chronic Hepatitis B (CHB) (10 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels at 24 weeks. Started Feb 2018; status: completed.
02
Drugs
bersacapavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03361956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03361956.